Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label phase 3 study of intravenous efgartigimod in adults with primary immune thrombocytopenia
NL-OMON55305Phase 3Withdrawn
- Sponsor
- argenx
- Start
- Jan 2020
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of efgartigimod alfa in immune thrombocytopenia (ITP), sponsored by argenx. Primary endpoint: Long-term safety. Planned start Jan 2020; status: withdrawn.
02
Drugs
efgartigimod alfa
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NL-OMON55305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55305.